Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29518426 | 1.00 | CCR1 (0.48) | CCR1NR4A2PDE10AHTR3EHTR3B | |
| SCHEMBL201434 | 0.86 | CCR1 (0.47) | CCR1NR4A2PDE10AHTR3AHRH3 | |
| SCHEMBL7086026 | 0.86 | NR4A2 (0.39) | CCR1NR4A2PDE10ACYP2A6 | |
| SCHEMBL27350783 | 0.85 | PDE10A (0.46) | NR4A2PDE10AHTR3EHTR3BHTR3A | |
| SCHEMBL3276372 | 0.82 | NR4A2 (0.47) | NR4A2PDE10AHTR3EHTR3BHTR3A | |
| SCHEMBL9203570 | 0.80 | CCR1 (0.48) | CCR1PDE10AHRH3DYRK1ALMNA | |
| SCHEMBL4348088 | 0.80 | LOXL2 (0.47) | NR4A2PDE10AHTR3EHTR3BHTR3A | |
| SCHEMBL13878246 | 0.80 | NR4A2 (0.46) | NR4A2PDE10AHTR3EHTR3BHTR3A | |
| SCHEMBL1911781 | 0.80 | NR4A2 (0.46) | NR4A2PDE10AHTR3EHTR3BHTR3A | |
| SCHEMBL28887330 | 0.80 | S1PR4 (0.49) | NR4A2PDE10AHTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105732583-B | A kind of target compound for treating Gliblastoma | 苏州麦迪耐斯医药科技有限公司 | 2018-05-04 | — | — | CN | claimed |
| CN-105732583-A | Targeted compound for treating glioblastoma multiforme | 苏州麦迪耐斯医药科技有限公司 | 2016-07-06 | — | — | CN | claimed |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| CN-105732583-B | A kind of target compound for treating Gliblastoma | 苏州麦迪耐斯医药科技有限公司 | 2018-05-04 | — | — | CN | disclosed |
| US-9682971-B2 | 1,2,5-Substituted benzimidazoles as flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | disclosed |
| US-9682972-B2 | 1,2,5-substituted benzimidazoles as flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | disclosed |
| CN-105732583-A | Targeted compound for treating glioblastoma multiforme | 苏州麦迪耐斯医药科技有限公司 | 2016-07-06 | — | — | CN | disclosed |
| US-20160108028-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-21 | — | — | US | disclosed |
| US-9290485-B2 | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| US-9290485-B2 | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| US-9290485-B2 | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| US-5021576-A | Antiinflammatory, antiarthritic, hypotensive, anticarcinogenic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-06-04 | — | — | US | disclosed |
| WO-1991006539-A1 | 2-ANILINO PHENYLACETIC ACID DERIVATIVES AS INHIBITORS OF PLA2 AND LIPOXYGENASE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-05-16 | — | — | WO | disclosed |
| EP-0419049-A1 | (Quinolin-2-ylmethoxy) indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA INC. (CA) | 1991-03-27 | — | — | EP | disclosed |
| EP-0399818-A1 | Diarylstyrylquinoline diacids | MERCK FROSST CANADA INC. (CA) | 1990-11-28 | — | — | EP | disclosed |
| EP-0349062-A1 | Quinoline ether alkanoic acid | MERCK FROSST CANADA INC. (CA) | 1990-01-03 | — | — | EP | disclosed |
| US-4851409-A | LEUKOTRIENE ANTAGONIST, ANTIASTHMA, ANTIALLERGEN, ANTIINFLAMMATORY, CYTOPROTECTIVE | MERCK FROSST CANADA INC. (CA) | 1989-07-25 | — | — | US | disclosed |
| EP-0318093-A2 | Diarylquinoline diacids and their use as medicaments | MERCK FROSST CANADA INC. (CA) | 1989-05-31 | — | — | EP | disclosed |
| EP-0271287-A2 | Quinoline dioic acids and amides | MERCK FROSST CANADA INC. (CA) | 1988-06-15 | — | — | EP | disclosed |
| EP-0233763-A2 | 2-Substituted quinoline dioic acids | MERCK FROSST CANADA INC. (CA) | 1987-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | CCR1 286/4885NR4A2 1340/4885PDE10A 4370/4885 |
| US-20160108028-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | FEN1, FOXM1, CYP3A5 | CCR1 311/4885NR4A2 2714/4885PDE10A 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.